Phosphatidylserine and the Dietary Supplement Listing Act: What US Buyers Should Prepare

The short answer is that, as of August 2026, the Dietary Supplement Listing Act of 2026 is a proposal, not law, but it tells U.S. PS buyers exactly which product and ingredient data FDA would expect, and that file should be built now, not after a bill passes. Senator Dick Durbin reintroduced S. 3677 on January 15, 2026, and Representative Maxine Dexter introduced the House companion H.R. 8370 on April 20, 2026. Both bills would add a new section to the Federal Food, Drug, and Cosmetic Act (FD&C Act) requiring dietary supplements marketed in the United States to be listed with FDA, using information that already exists on the label and in the product file.

For a bulk phosphatidylserine (PS) buyer, the practical trigger is supplier data. A supplement listing is not an ingredient certificate, but it leans on ingredient documents: exact ingredient naming, amount per serving, allergen position, manufacturer identity, lot traceability, and change control. This article explains what the bills propose, who would file, which PS documents map to the listing fields, and what buyers should prepare now without treating pending legislation as current law. It is a B2B preparation guide, not legal or medical advice.

What the Dietary Supplement Listing Act of 2026 Proposes

The 2026 proposal is the latest version of a long-running transparency effort. Under DSHEA, dietary supplements do not receive premarket approval, and manufacturers are responsible for safety and labeling before marketing. Senator Durbin's office notes that DSHEA did not require companies to register products with FDA, which now estimates more than 100,000 supplements are on the market, up from roughly 4,000 in 1994. CRN cites about 80,000 products and a 2019 Pew survey in which nearly nine in ten U.S. adults favored giving FDA product information.

The bills would add a new section 403D to the FD&C Act. In short, each dietary supplement marketed in the United States would need to be listed with FDA, and the listing would include:

Two features matter for ingredient buyers. First, the bill preserves the DSHEA framework: it does not authorize premarket approval of supplements. Second, it would make an unlisted product misbranded and add a prohibited act tied to supplements prepared, packed, or held with the assistance of a person debarred under FD&C Act section 306.

The timing in the bills is also concrete. Products already on the market on or before January 1, 2027, would need to be listed within 18 months after enactment; products not on the market before that date would be listed when first introduced into interstate commerce. A responsible person would notify FDA within one year after discontinuing a product, update a listing within 30 days after a changed product is first introduced, and answer FDA requests for additional information within 10 calendar days. FDA would have two years after enactment to build a publicly searchable electronic database.

Who Files the Listing, and Why the Supplier Matters

Under the bills, the responsible person is the manufacturer, packer, or distributor whose name appears on the label under FD&C Act section 403(e)(1). If that party is a foreign entity, a U.S. agent would submit the listing. For most U.S. supplement brands and private-label buyers, that means the brand or importer of record is the responsible person, not the bulk ingredient manufacturer. The manufacturer is the data source behind the listing.

That split creates a concrete documentation dependency. The same bill section says that, upon request from FDA, the responsible person must provide, within 10 calendar days, the full business names and physical and mailing addresses of all locations where the supplement is manufactured, packaged, labeled, or held, as well as the addresses from which the responsible person receives the dietary ingredient or combination of ingredients used in the product. For a PS supplement, that means the supplier chain must be documentable: who manufactured the PS, where, and through which route it reached the formulator or packer.

This is one reason listing readiness is a supplier-qualification question, not only a label question. A buyer can assemble a clean Supplement Facts label and still fail if the manufacturer identity, facility details, or ingredient source addresses cannot be confirmed in writing.

The Ingredient Data Behind a PS Listing

The most supplier-intensive part of a listing is the ingredient data. The bills refer back to 21 CFR 101.4 and 101.36, the same regulations that drive the Supplement Facts panel. Under 101.36, an ingredient such as phosphatidylserine, which has no established Reference Daily Intake or Daily Reference Value, is declared as an "other dietary ingredient" by its common or usual name, with the quantitative amount per serving in metric units and a "Daily Value not established" footnote.

For a PS product, that creates several alignment checks:

• Ingredient name. The name on the Supplement Facts panel should match the specification and COA. "Phosphatidylserine" is the dietary ingredient; the source route is separate product positioning ("Soy Phosphatidylserine" or "Sunflower Phosphatidylserine") that should stay consistent across the label, spec, and supplier documents.
• Amount per serving. The declared milligrams per serving should trace to the finished formula and the ingredient's assay basis.
• Proprietary blends. If PS sits inside a proprietary blend, the bill keeps the blend quantities confidential.
• Allergens. Soy-derived PS is tied to soy, a major food allergen, while sunflower PS offers a non-soy position. The allergen statement should match the source route documented by the supplier, as covered in the allergen statement review.
• Claims. Any structure/function or disease-related claim on the label would be part of the listing. The structure/function claims guide covers how claim classification, substantiation, and FDA notification interact with ingredient evidence.

The takeaway is that a listing-ready file is a three-way match between the finished label, the formula, and the supplier's specification and COA evidence. Discrepancies between the name on the COA and the name on the label are exactly the kind of gap a listing process would expose.

Supplier Documents That Make a PS File Listing-Ready

Even before any bill becomes law, buyers can treat the proposal as a checklist prompt for the supplier document pack. For bulk PS, the practical list is:

1. Current specification. Exact ingredient name, source route, PS assay basis, grade, carrier, and packaging.
2. Current COA. Lot-linked results matching the specification, with the same ingredient naming used on the label.
3. Manufacturer identity. Full business name and address, plus facility-registration support, consistent across the COA, invoice, and label.
4. Allergen position. A soy statement or the non-soy documentation for sunflower PS, tied to the actual lot.
5. Traceability. Lot codes and the manufacturer-to-packer route, so the receiving chain can be reconstructed if FDA asks for ingredient source addresses.
6. Change control. A written commitment to notify the buyer of any source, specification, process, or site change, so a potential listing update can be evaluated.

The lot traceability checklist and the repeat-order document review describe how to request and maintain this evidence. The listing proposal adds a reason to keep those files current: a changed product would trigger a listing update within 30 days, and a buyer who cannot tell whether a supplier change was material cannot meet that deadline.

How Listing Fits With the Current U.S. Framework

Buyers sometimes assume listing would duplicate obligations they already handle. It would not. The current U.S. framework is a set of separate layers, and the proposal would add a product-level registry on top of them:

The facility registration guide covers the registration layer, and the NDI review covers the new-ingredient lane. Neither answers the listing question, and the bills would make the listing failure itself a misbranding violation. CRN stresses that the proposal is a transparency tool, not a new approval gate, which is why the preparation burden falls on documentation rather than on FDA review.

For buyers, the practical difference is timing. Registration is a facility-level snapshot; a listing is a product-level record that would need to stay current with every label, formula, or ingredient-source change. That is a change-control discipline, not a one-time filing.

What U.S. PS Buyers Should Do Now

The most useful action today is to build the product file as if the listing fields were live, without claiming that the bills are law. A practical sequence:

1. Lock the finished-product identity. Brand name, statement of identity, form, flavors, and package sizes.
2. Lock the ingredient name. Confirm how PS appears on the Supplement Facts panel and that it matches the supplier spec and COA.
3. Confirm the responsible person. Decide which entity appears on the label and, if it is foreign, which U.S. agent would handle FDA submissions.
4. Verify manufacturer and facility data. Align the label business name with the manufacturer identity, addresses, and registration support.
5. Confirm allergen and claim files. Match the soy or sunflower source route to the allergen statement, and keep claim notifications current.
6. Set a change-control trigger. Ask the supplier to notify you of source, spec, process, or site changes, and review each against a potential 30-day listing update.
7. Track the legislation. Follow the bill's committee status through Congress and FDA communications rather than assuming enactment.

Need a listing-ready PS document package?

If your team is assembling a U.S. product file and needs current specification, COA, source-route, manufacturer-identity, and change-control evidence for soy or sunflower PS, contact Nutranexa sales with your target grade, source preference, finished format, and market.

How Verified Nutranexa Facts Fit the Review

Nutranexa is a functional food ingredient manufacturer focused on phosphatidylserine, soy PS, sunflower PS, and soluble soybean polysaccharide. Published facts state that the company was founded in 2013, operates a 110,000+ m2 campus, primarily exports to Europe and North America, and offers PS with a 25 kg MOQ and 25 kg net per drum. The site provides specification and COA evidence, manufacturing context, packaging and dispatch imagery, and R&D cooperation references.

Those facts help a buyer define the commercial item that would feed a listing: exact source route, grade, specification basis, packaging, and manufacturer identity. They do not establish that any finished product is listing-ready, that FDA has approved any product, or that the pending bills are in force. Buyers should confirm current documents, lot-level details, and labeling language with the supplier and their own regulatory advisors.

Preguntas frecuentes

Is the Dietary Supplement Listing Act law yet?

No. As of August 2026, S. 3677 and H.R. 8370 are proposals pending before the Senate Health, Education, Labor, and Pensions Committee and the House Energy and Commerce Committee. Treat the bill framework as a preparation checklist, not a current filing requirement.

Would the DSLA require FDA approval of a PS supplement?

No. The 2026 bills preserve DSHEA and do not authorize premarket approval of dietary supplements. Listing would be a transparency and registry requirement: products would be reported with information already found on labels and product files, and failure to list would be treated as misbranding.

What information would a PS supplement listing include?

Under the bills, the listing would include product name and identity, responsible-person and U.S. agent information, an electronic label copy, all ingredients and amounts per serving, servings per container, directions for use, allergen statements, product form, claims on the label, and an FDA-assigned listing number.

What PS ingredient documents should buyers prepare now?

Start with the current specification and COA using the same ingredient naming as the label, manufacturer identity and address, allergen position for soy or sunflower PS, lot traceability, and a supplier change-control commitment. These map directly to the listing fields and to the 10-calendar-day information request the bills describe.

Does supplement listing replace facility registration or NDI?

No. Facility registration, NDI notification, Supplement Facts labeling, and claim notification each answer a different question. The listing proposal would add a product-level registry and make the listing file dependent on ingredient and supplier data from those other layers.

What supplier changes would require a PS listing update?

Under the bills, a change to information on the label of an already-listed product would need to be submitted within 30 days after the changed product is first introduced into interstate commerce. Source-route, spec, formula, or manufacturing-site changes should therefore be evaluated as potential listing updates, which is why buyer-side change control matters.

Conclusion

The Dietary Supplement Listing Act of 2026 is not a distant abstraction for PS buyers. Whether or not the current bills pass, they define the product and ingredient data a U.S. supplement listing would require, and most of that data sits in the supplier file: exact ingredient naming, amount per serving, manufacturer identity, allergen position, lot traceability, and change control.

The practical rule is simple. Build the product file as if the listing fields were live: align the label, formula, spec, and COA; confirm the responsible person and manufacturer data; and keep supplier change notifications current. That discipline reduces downstream rework whether the bill becomes law, is amended, or is replaced by another framework.

Fuentes

• Congress.gov: S. 3677 - Dietary Supplement Listing Act of 2026
• Congress.gov: H.R. 8370 - Dietary Supplement Listing Act of 2026
• Senator Dick Durbin: Durbin Introduces Legislation To Improve Transparency And Safety Of Dietary Supplements
• CRN: CRN-Backed Product Listing Proposal Reintroduced, Advancing Long-Standing Push for Transparency in Dietary Supplements
• CRN: Advancing a Dietary Supplement Registry
• FDA: Dietary Supplements
• eCFR: 21 CFR 101.36 - Nutrition labeling of dietary supplements
• eCFR: 21 CFR 1.225 - Registration of food facilities

Contactar con Ventas

Contact Nutranexa sales to request the current PS specification, available COA evidence, source-route and allergen position, manufacturer identity, packaging details, and lot-traceability support for the soy or sunflower route you plan to use in a U.S. product file. Share your target grade, finished format, label ingredient name, and market so the document set can be matched to your listing-readiness review.

Próximos pasos recomendados

• Revisa el Phosphatidylserine página del producto.
• Comparar Soy PS y Sunflower PS.
• Verificar prueba de fabricación y Calidad e I+D.